Compare VINP & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VINP | ZVRA |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 638.8M | 741.9M |
| IPO Year | 2020 | 2015 |
| Metric | VINP | ZVRA |
|---|---|---|
| Price | $9.84 | $13.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $14.00 | ★ $23.00 |
| AVG Volume (30 Days) | 63.3K | ★ 1.8M |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.72% | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | N/A | ★ 0.60 |
| Revenue | N/A | ★ $106,470,000.00 |
| Revenue This Year | $18.07 | $37.27 |
| Revenue Next Year | $12.74 | $53.42 |
| P/E Ratio | $24.41 | ★ $23.90 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $9.20 | $7.16 |
| 52 Week High | $13.61 | $14.58 |
| Indicator | VINP | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 47.73 | 65.65 |
| Support Level | $9.66 | $8.26 |
| Resistance Level | $10.88 | $14.27 |
| Average True Range (ATR) | 0.38 | 0.61 |
| MACD | 0.03 | 0.09 |
| Stochastic Oscillator | 30.66 | 73.75 |
Vinci Compass Investments Ltd is an alternative investment platform in Brazil offering asset management, wealth management, and financial advisory services. The company comprises of six business lines i) Global IP&S, (ii) Credit (including public & private credit, opportunistic capital solutions, and agribusiness credit), (iii) Private Equity, (iv) Equities, (v) Real Assets (including real estate, infrastructure and forestry) and (vi) Corporate Advisory.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.